Working… Menu
Trial record 55 of 389 for:    CLARITHROMYCIN

Intravenous Clarithromycin in Septic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00297674
Recruitment Status : Completed
First Posted : February 28, 2006
Last Update Posted : February 28, 2006
Information provided by:
University of Athens

Brief Summary:
The aim of this clinical trial is to clarify the clinical efficacy of clarithromycin as immunotherapy for the management of septic syndrome by ventilator-associated pneumonia.

Condition or disease Intervention/treatment Phase
Sepsis Ventilator Associated Pneumonia Drug: Intravenous Clarithromycin Phase 4

Detailed Description:
The rationale of the trial is based on the favorable results of experimental studies of sepsis by multidrug-resistant Pseudomonas aeruginosa and by susceptible Escherichia coli in rabbits where clarithromycin was administered intravenously. Data from these latter studies suggest that administration of clarithromycin extended survival and attenuated systemic inflammatory response. Their major endpoint was successful immunotherapy achieved when clarithromycin was administered on presentation of symptoms of sepsis-induced pulmonary edema; on the contrary, former clinical trials for immunotherapies of sepsis were based on animal studies where the under evolution immunomodulator was administered before bacterial challenge. The efficacy of administration of clarithromycin upon presentation of septic syndrome in animal studies, renders its application promising in the clinical field.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Clarithromycin as Immunomodulatory Therapy for the Management of Septic Syndrome by Ventilator-Associated Pneumonia
Study Start Date : June 2004
Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Primary Outcome Measures :
  1. Estimation of crude mortality by any reason of each study group
  2. Estimation of attributable mortality by VAP of each study group
  3. 7-day mortality rate of each group
  4. 28-mortality rate of each group
  5. Rate of progression to multiple organ failure and septic shock (and number of failing organs) of each study group
  6. Time to progression to multiple organ failure and septic shock of each study group
  7. Days of resolution of VAP
  8. Days in ICU after diagnosis of VAP

Secondary Outcome Measures :
  1. Influence of administration of clarithromycin on systemic inflammatory response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. written informed consent provided by first or second degree relatives;
  2. intubation and mechanical ventilation at least 48 hours prior to enrolment; c) age of patients equal to or more than 18 years;

d) diagnosis of Ventilator Associated Pneumonia; and e) signs of sepsis

Exclusion Criteria:

  1. neutropenia, defined as less than 500 neutrophils/mm3;
  2. HIV infection;
  3. oral intake of corticosteroids at a dose equal to or higher than 1mg/kg equivalent prednisone for a period greater than one month;
  4. administration of drotrecogin alpha the last five days prior to enrolment; and e) atrioventricular block of second or third degree.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00297674

Layout table for location information
1st Department of Critical Care, Evangelismos General Hospital
Athens, Greece, 106 72
2nd Department of Critical Care, ATTIKON University Hospital
Athens, Greece, 124 64
4th Department of Internal Medicine, ATTIKON University Hospital
Athens, Greece, 124 64
Sponsors and Collaborators
University of Athens
Layout table for investigator information
Study Chair: Evangelos J Giamarellos-Bourboulis, MD, PhD University of Athens, Medical School, Greece
Principal Investigator: Helen Giamarellou, MD, PhD University of Athens, Medical School, Greece
Principal Investigator: Apostolos Armaganidis, MD, PhD University of Athens, Medical School, Greece
Principal Investigator: Charis Roussos, MD, PhD University of Athens, Medical School, Greece

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00297674     History of Changes
Other Study ID Numbers: ACA-GREC-2004-01
First Posted: February 28, 2006    Key Record Dates
Last Update Posted: February 28, 2006
Last Verified: July 2004
Keywords provided by University of Athens:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Cross Infection
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors